

BONNIE J. ADDARIO LUNG CANCER FOUNDATION (ALCF) & ADDARIO LUNG CANCER MEDICAL INSTITUTE (ALCMI)

The power of two makes us different. Working together to extend patient lives.

WHO WE ARE AND WHAT WE DO

Two “sister” patient-founded 501(c)3 organizations working together and autonomously, leveraging our respective resources and expertise, to significantly impact, accelerate and increase lung cancer patient survival.

- ALCF focuses on research, patient support, education, empowerment, awareness and advocacy, giving patients and families a road map to guide them and a support system to anchor them.
- ALCMI focuses on scientific and clinical research advancements, investing and driving initiatives in genetic testing, therapeutic discoveries, targeted treatments and early detection.

ONE GOAL
Transform lung cancer into a manageable, chronic disease by 2023 and ultimately facilitate cures.

WHY? In the past 45 years, the 5-year patient survival rate of 16% has not significantly changed.

THIS IS UNACCEPTABLE.

HOW? ATTACKING LUNG CANCER ON TWO FRONTS

ALCF and ALCMI work in tandem and as a team with each organization contributing its singular expertise AND joining together to power collaborative initiatives. Through game-changing ALCF PATIENT SERVICES programs and new and novel ALCMI RESEARCH, these organizations get to know patients, acting on their behalf to provide and fund direct services needed to live with the disease today AND identify and drive clinical research required to improve patient outcomes tomorrow. Patients now have two organizations—ALCF and ALCMI—fighting to make sure that their lungs and their lives can be cancer free!



BONNIE J. ADDARIO
LUNG CANCER
FOUNDATION

ALCMI

‘al-kə-mē

ADDARIO
LUNG CANCER
MEDICAL INSTITUTE

continued on back

ALCF PATIENT SERVICES

- The Living Room—Monthly Support Group with expert speakers “Bringing Hope Home” via live-streaming to 150 countries.
- Navigating Lung Cancer: 360° of Hope—Patient Education Handbook/Mobile Application putting critical knowledge directly into the hands of thousands
- Patient 360 Community Hospital Program—Initiative improving standard of care by reducing time from molecular testing to treatment from 45 to 15 days
- Direct Patient/Family Guidance—Hands-on, personal assistance to thousands annually

AWARENESS—Our message is urgent and simple; patients hold the key to unlocking the mystery of lung cancer. They must have a “seat at the table” and “voice” in the discussion about treatment and care. We deliver our message and provide a unifying voice through creative campaigns, social and traditional media. Our annual reach is 160 million impressions.

EVENTS—“Call to Action” events deliver our message across the U.S. and help raise funds to support our mission-based work.

JILL’S LEGACY—Our advisory board of empowered 18-35 year-old patients and young adults touched by lung cancer conveys the message that the disease does not discriminate based on age, gender, race or background. Anyone can get lung cancer.

Through your tax-deductible donations, we can accelerate research breakthroughs that patients urgently need.
ALCF Tax ID: 20-4417327 • ALCMI Tax ID: 26-1721868

ALCMI COLLABORATIVE RESEARCH

ALCMI’s unique contractual research consortium facilitates basic and clinical research to accelerate the discovery and delivery of advancements to patients.

By bringing together a world-class team of lung cancer scientists and clinicians from over 20 academic and community medical centers in the U.S. and Europe, ALCMI has rapidly established a critical mass of scientific and operational expertise and infrastructure linked together to benefit patients through focused research.

■ **CASTLE**: This clinical trial enables molecular testing for informed therapeutic decision-making by patients and their physicians while also centrally collecting tumor, DNA, RNA and blood samples with clinical data, establishing a one-of-a-kind platform for researchers globally.

■ **INHERIT**: This study is identifying specific inherited gene alterations that raise the risk of developing lung cancer in patients and family members, irrespective of smoking history.

■ **GENOMICS OF YOUNG LUNG CANCER**: As the first international lung cancer genomics study, we are collecting and sequencing tumor and blood samples in patients first diagnosed under age 40. This study aims to identify acquired and inherited risk factors while providing personalized treatment guidance to enrolled patients today.